Research Article Volume 122 | Issue 3 | March 2014
Environ Health Perspect; DOI:10.1289/ehp.1307545
Chronic Arsenic Exposure and Angiogenesis in Human Bronchial Epithelial Cells via the ROS/miR-199a-5p/HIF-1α/COX-2 Pathway
Jun He,1,2 Min Wang,1 Yue Jiang,3 Qiudan Chen,1 Shaohua Xu,4 Qing Xu,2 Bing-Hua Jiang,1,2 and Ling-Zhi Liu2
Background: Environmental and occupational exposure to arsenic is a major public health concern. Although it has been identified as a human carcinogen, the molecular mechanism underlying the arsenic-induced carcinogenesis is not well understood.
Objectives: We aimed to determine the role and mechanisms of miRNAs in arsenic-induced tumor angiogenesis and tumor growth.
Methods: We utilized an in vitro model in which human lung epithelial BEAS-2B cells were transformed through long-term exposure to arsenic. A human xenograft tumor model was established to assess tumor angiogenesis and tumor growth in vivo. Tube formation assay and chorioallantoic membranes assay were used to assess tumor angiogenesis.
Results: We found that miR-199a-5p expression levels were more than 100-fold lower in arsenic-transformed cells than parental cells. Re-expression of miR-199a-5p impaired arsenic-induced angiogenesis and tumor growth through its direct targets HIF-1α and COX-2. We further showed that arsenic induced COX-2 expression through HIF-1 regulation at the transcriptional level. In addition, we demonstrated that reactive oxygen species are an upstream event of miR-199a-5p/ HIF-1α/COX-2 pathway in arsenic-induced carcinogenesis.
Conclusion: The findings establish critical roles of miR-199a-5p and its downstream targets HIF-1/COX-2 in arsenic-induced tumor growth and angiogenesis.
Citation: He J, Wang M, Jiang Y, Chen Q, Xu S, Xu Q, Jiang BH, Liu LZ. 2014. Chronic arsenic exposure and angiogenesis in human bronchial epithelial cells via the ROS/miR-199a-5p/HIF-1α/COX-2 Pathway. Environ Health Perspect 122:255–261; http://dx.doi.org/10.1289/ehp.1307545
Address correspondence to B.-H. Jiang, Thomas Jefferson University, 1020 Locust St., Philadelphia, PA 19107 USA. Telephone: (215) 503-6147. E-mail: firstname.lastname@example.org or to L.-Z. Liu, Thomas Jefferson University, 1020 Locust St., Philadelphia, PA 19107 USA. Telephone: (215) 503-6148. E-mail: Ling-Zhi.Liu@jefferson.edu
This work was supported in part by grants from the National Natural Science Foundation of China (81071642 and 30871296), Jiangsu Province’s Key Discipline of Medicine (XK201117), and by the National Institute of Environmental Health Sciences, National Institutes of Health (R01ES020868).
The authors declare they have no actual or potential competing financial interests.
Received: 25 August 2013
Accepted: 6 January 2014
Advance Publication: 10 January 2014
Final Publication: 1 March 2014
- Supplemental Material (483 KB) PDF
Arsenic is a widely distributed semimetallic element that occurs naturally in various compounds in the crust of the earth. Approximately 160 million people worldwide are exposed to unsafe high levels of arsenic in drinking water (Hubaux et al. 2013). In particular, about 25 million people in Bangladesh and 6 million in India are chronically exposed to a very high level of arsenic exceeding 50 μg/L via groundwater (Rahman et al. 2001), which is significantly greater than the current maximum contaminant level (MCL) of 10 μg/L set forth by the U.S. Environmental Protection Agency (2014). Long-term arsenic exposure leads to an increased risk of skin, bladder, and liver cancers and, especially, lung cancer. Epidemiological investigations and laboratory studies have provided evidence that ingestion of arsenic via drinking water or inhalation of air increases the risk of lung cancer in a dose–dependent way (Boffetta 2004; Chen et al. 2004). However, the exact mechanism of arsenic-induced cell malignant transformation and cancer development remains to be investigated.
Current proposed mechanisms underlying arsenic carcinogenesis include arsenic-induced genetic changes and epigenetic alterations (Hubaux et al. 2013). The epigenetic alterations consist of histone modification, DNA methylation, and microRNA (miRNA) regulation. We and others (Beezhold et al. 2011; He et al. 2013b; Wang et al. 2011) have observed aberrant miRNA expression profiles after heavy-metal exposure in various cell types, which indicates the involvement of miRNAs in environmental carcinogenesis. However, it remains to be determined whether these miRNAs play causal roles in arsenic-induced tumor initiation and development.
Angiogenesis is the formation of new blood vessels from existing vasculatures to induce tumor growth. Outside of its role in physiological processes such as embryo development and wound healing, angiogenesis is required for cancer development. Angiogenesis is critical for a tumor colony to grow and become invasive (D’Amico 2004). In the present study, we aimed to determine a) the roles of miRNAs in arsenic-induced tumor angiogenesis and tumor growth, b) the direct targets of miRNAs in regulating tumorigenesis, and c) the functional relevant angiogenesis factors in arsenic- and miRNA-mediated carcinogenesis.
Materials and Methods
Cell culture and generation of stable cell lines. Human bronchial epithelial BEAS-2B cells [American Type Culture Collection (ATCC), Manassas, VA, USA] were cultured in DMEM (Dulbecco’s modiﬁed Eagle’s medium; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS). Human umbilical vein endothelial cells (HUVEC) (purchased from ATCC) were cultured in EBM-2 (endothelial basal medium-2) complete medium. Arsenic-transformed BEAS-2B (AsT) cells (Carpenter et al. 2011) stably overexpressing miR-199a or miR-control were generated by infecting BEAS-2B cells with lentivirus carrying miR-199a-RFP or a negative control precursor (Applied Biosystems, Carlsbad, CA, USA), followed by selection with puromycin. To establish stable cell lines overexpressing COX-2 (cyclooxygenase-2), 293T cells were transfected with lentivirus carrying the COX-2 plasmid (GeneCopoeia, Rockville, MD, USA) or an empty vector to generate infectious virus. Then AsT cells were transduced with virus, followed by the puromycin selection. We also prepared PI3K (phosphatidylinositide 3-kinase)–transformed chicken embryo fibroblast cells as was previously described (Chang et al. 1997; Jiang et al. 2000).
Animal experiment. Female CrTac:NCr-Foxn1nu mice (8 weeks of age) were purchased from Taconic (Hudson, NY, USA), and maintained in pathogen-free conditions. Animals were housed in sterilized cages (5 mice/cage) with hardwood chip bedding. Standardized commercial diets were provided, and sterilized water was available at all times. The average weight of animals on arrival was 20 ± 2 g (mean ± SD). A total of 2 × 106 AsT/miR-cont cells or AsT/miR-199a cells (AsT cells stably overexpressing miR-control or miR-199a, respectively) in 80 μL were injected subcutaneously into the flanks of nude (nu/nu) mice (n = 10/group). The animals used in research were treated humanely according to the Institutional Animal Care and Use Committee of Thomas Jefferson University. The mice were euthanized by decapitation 6 weeks after injection. Tumor tissues were removed and weighed. Parts of tissues were paraffin-embedded, and other parts were snap-frozen in liquid nitrogen and stored at –80°C for immunohistochemical analysis.
Reagents and antibodies. Sodium arsenic, catalase, and H2O2 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Small interfering RNA (siRNA) Smartpools (pools of four individual siRNAs) against COX-2, HIF-1α (hypoxia inducible factor 1, alpha), and a scrambled control were purchased from Dharmacon (Lafayette, CO, USA). COX-2 antibody was from Cell Signaling Technology (Beverly, MA, USA). CD31 (platelet/endothelial cell adhesion molecule 1) antibody for analyzing paraffin-embedded tissues was from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and for analyzing frozen tissues, from BD Pharmingen (San Jose, CA, USA). HIF-1α antibody was from BD Biosciences (Franklin Lakes, NJ, USA), and α-SMA (smooth muscle α-actin) antibody was obtained from Abcam (Cambridge, MA, USA). Primary antibodies used for Western analysis were diluted 1:1,000 in 5% bovine serum albumin as a working concentration and were incubated on a shaker overnight at 4°C.
RT-qPCR analysis. Total RNAs were extracted using Trizol (Life Technologies, Carlsbad, CA, USA). The synthesis of cDNA was performed using oligo (dT)18 primers and M-MLV (Moloney Murine Leukemia Virus) reverse transcriptase (Promega, Madison, WI, USA). The amplification was performed by polymerase chain reaction (PCR). SYBR-green reverse transcription PCR (RT-qPCR) was performed to detect COX-2 and GADPH (glyceraldehyde-3-phosphate dehydrogenase) mRNA levels using the Power SYBR Green PCR Master Mix Kit (Applied Biosystems). Taqman RT-qPCR was performed to detect miRNA expression levels using the Taqman miRNA Reverse Transcription kit and Taqman universal PCR Master Mix (Applied Biosystems). The sequences of primer used for SYBR-green RT-qPCR were as follows:
- COX-2 forward: 5´-TCAGCCATACAGCAAATCCTT-3´
- COX-2 reverse: 5´-CTGCACTGTGTTAGTGG-3´
- GAPDH forward: 5´-ATGGGTGTGAACCATGA GAAGTATG-3´
- GADPH reverse: 5´GGTG CAGGAGGCATTGCT-3´.
Immunohistochemistry and immunofluorescence. Paraffin-embedded tissue sections and frozen tissue sections were prepared by routine methods (Fero Lab, Fred Hutchinson Cancer Research Center 2011). For immunohistochemistry, the Dako Envision two-step method of immunohistochemistry was used to stain CD31 (1:100 dilution) and α-SMA (1:150 dilution) in xenograft tumor tissues as described previously (He et al. 2012a). Tissue sections were incubated with primary antibodies in a humid chamber overnight at 4°C. The microvessel density reflected by CD31-positive staining was counted in three different fields per section. For immunofluorescence staining, frozen sections were incubated with primary antibodies overnight. Goat anti-rabbit or anti-mouse IgG conjugated with fluorescein isothiocyanate or Texas Red (both from Santa Cruz Biotechnology) (1:200 dilution) were used as secondary antibodies and incubated for 2 hr at room temperature. Slides were mounted with anti-fade DAPI reagent (Invitrogen, Grand Island, NY, USA).
Chromatin immunoprecipation (ChIP)–quantitative PCR (qPCR). ChIP-qPCR was performed using the EpiTect ChIP OneDay Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s instructions. HIF-1α antibody (Abcam) was used to pull down the protein–chromatin complexes. Rabbit IgG was used as a negative control. The immunoprecipated DNA was quantified using SYBR Green qPCR (Applied Biosystems). All results were normalized to 1% input value of the same sample. COX-2 primers flanking the hypoxia-response elements (HRE) for SYBR Green qPCR were as follows:
- Forward: 5´-TATACAGCCTATTAAGCGTCGTCA-3´
- Reverse: 5´-CGTGTCTGGTCTGTACGTCTTAG-3´.
Prostaglandin E2 (PGE2) ELISA. Cells were plated at 0.1 × 106 cells/well of a 24-well plate and allowed to recover overnight. The following day, the media were replaced with fresh media, and then the cells were cultured in normoxia or hypoxia (1% O2) for 24 hr. The conditioned media were then collected and cleared of cellular debris by centrifugation at 2,000 rpm for 2 min. PGE2 concentrations were determined using the Prostaglandin E2 EIA Kit–Monoclonal ELISA kit (no. 514010; Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer’s instructions.
miRNA luciferase reporter constructs and luciferase activity assay. The 3´UTR-luciferase reporter constructs containing the 3´UTR regions of COX-2 with wild-type and mutant binding sites of miR-199a were amplified using the PCR method (GoTaq® G2 Flexi DNA Polymerase; Promega) according to the manufacturer’s instructions. The PCR products were cloned into the pMiR-luc luciferase reporter vector (Ambion, Grand Island, NY, USA). The mutant 3´UTR constructs were made by introducing four point mutations into the putative seed regions of COX-2. All the constructs containing 3´UTR inserts were sequenced and verified. The luciferase activity assay was performed as previously described (He et al. 2013a).
Site-directed mutagenesis. The human full-length COX-2 reporter used was a generous gift from J. Li (Harvard University, Boston, MA, USA) (Wu et al. 2006). To generate the HRE-mutant COX-2 reporter, we performed site-directed mutagenesis on the wild-type COX-2 reporter at the potential HIF-1α binding sites with 3 base pair substitutions as previously described (Jiang et al. 1996). The mutant COX-2 reporter construct was validated by DNA sequencing.
Tube formation assay. HUVEC were cultured in EBM-2 complete medium, and switched to EBM-2 basal medium containing 0.2% FBS for 24 hr before performing the tube formation assay. The conditioned media were prepared from different cells by replacing normal culture medium with serum-reduced medium (1% FBS). After culture for 24 hr, the serum-reduced media were collected and stored at –20°C for later use. The HUVEC were trypsinized, counted, and resuspended in EBM-2 basic medium; then they were mixed with an equal volume of the conditioned medium and seeded on Matrigel-pretreated 96-well plates at 2 × 104 cells/well. After culture for 6-12 hr, tube formation was observed under a light microscope and photographed. The total lengths of the tubes in each well were measured using CellSens Standard software (Olympus; Hamburg, Germany).
The chorioallantoic membranes (CAM) assay. White Leghorn fertilized chicken eggs (Charles River, Malvern, PA, USA) were incubated at 37°C under constant humidity. Cells were transfected with miRNA precursors, or treated as specifically indicated in the figure legends. After transfection for 12 hr, the cells were trypsinized, counted, and resuspended in the serum-free medium. The cell suspensions were mixed with Matrigel at a 1:1 ratio, and implanted onto the CAM of chicken eggs on day-9 embryos. Tumor angiogenesis responses were analyzed 5 days after the implantation. The tumor/Matrigel plugs were trimmed off the CAM and photographed. The number of blood vessels as the index of angiogenesis was analyzed by counting the branches of blood vessels in three representative areas (each 1.0 mm2) by two observers in a double blind manner.
miRNA transfection. Cells were cultured in 6-well plates to reach a 60% confluency, and transfected using miR-199a or a negative-control precursor (both from Applied Biosystems) at 30 nM using Lipofectamine RNAiMAX reagent (Invitrogen, Grand Island, NY, USA) according to the manufacturer’s instructions. Total proteins and RNAs were prepared from the cells 60–70 hr after the transfection, followed by Western blotting or RT-PCR analysis.
Hypoxia treatment. A hypoxia incubator chamber (Stemcell, Vancouver, British Columbia, Canada) was used to generate the hypoxia environment for cell culture. Cells were cultured in hypoxia conditions (1% O2) for 24 hr at 37°C.
Reactive oxygen species (ROS) study. Cells were treated with ROS scavenger catalase (1,500 U) or with H2O2 (50 μM) for 12 hr. Then cells were harvested, and total proteins were extracted for Western blotting analysis.
Statistical analysis. All the results were obtained from at least three independent experiments. Results are presented as mean ± SE and were analyzed by Student’s t-test or one-way analyis of variance (ANOVA). All results were analyzed by SPSS for Windows, version 11.5 (IBM, Chicago, IL, USA). Differences were considered significant with p < 0.05.
miR-199a-5p is down-regulated in AsT cells. In order to investigate the mechanism of arsenic-induced carcinogenesis, we previously established an in vitro model by transforming immortalized human lung epithelial BEAS-2B cells via chronic exposure to 1 μM sodium arsenic for 26 weeks (Carpenter et al. 2011). BEAS-2B cells cultured in arsenic-free medium served as a passage-matched control. We performed miRNA microarray analysis to compare the miRNA profiles between parental cells (BEAS-2B) and AsT cells. We found that miR-199a (referred to miR-199a-5p) was the most down-regulated miRNA among the list of miRNAs examined (data not shown). We further validated the result by performing Taqman RT-qPCR analysis. As shown in Figure 1A, miR-199a was 100-fold lower in AsT cells, indicating a major change of miRNA abundance in cell malignant transformation (He et al. 2013b). To investigate the relationship between arsenic treatment and miR-199a expression, we treated BEAS-2B cells with sodium arsenic at the doses of 0.5 μM, 1 μM, and 2 μM for 24 hr. miR-199a expression levels were significantly decreased by arsenic treatment at the dose of ≥ 1 μM (Figure 1B). To determine whether cell transformation affects miR-199a expression, we tested two different types of cell lines transformed by oncogenes: the AsT cells and PI3K–transformed chicken embryo fibroblast cells described above. miR-199a levels were decreased in transformed cells compared with the parental control cells, but the difference was not statistically significant (see Supplemental Material, Figure S1). We also used newly transformed immortalized RE3K rat kidney cells [by N-Ras (neuroblastoma Ras)] (Kolligs et al. 1999) (see Supplemental Material, Figure S2A). We found that miR-199a expression levels in N-Ras–transformed cells were 1.9-fold lower compared with the control cells (see Supplemental Material, Figure S2B), indicating that transformation and/or oncogenes may decrease miR-199a expression. However, given that miR-199a expression levels were more than 100-fold lower in AsT cells, we reason that arsenic plays a major role in the suppression of miR-199a expression.
miR-199a inhibits arsenic-induced angiogenesis in vitro and in vivo. Our earlier study (He et al. 2013a) showed that miR-199a processes an anti-angiogenic property in ovarian cancer cells. We then investigated the functional effect of miR-199a in arsenic-induced angiogenesis by performing a tube formation assay in vitro. As shown in Figure 2A, tube formation was strongly induced when cultured in conditioned medium prepared from AsT cells as compared with its parental control BEAS-2B cells. Transient transfection of miR-199a in AsT cells decreased tube formation by 40%. We next investigated the angiogenic effect of miR-199a in vivo. First, we established AsT cells stably expressing miR-199a by transducing lentivirus-carrying miR-199a-RFP. Then we generated xenograft tumors by injecting the stable cells AsT/miR-cont and AsT/miR-199a subcutaneously in nude mice and allowed tumors to grow for 6 weeks. Overexpression of miR-199a decreased the tumor weight by 50% as compared with negative control cells (Figure 2B). The number of microvessels indicated by the endothelial marker CD31 staining in miR-199a–overexpressing tumors was significantly lower than in the control (Figure 2C). As in normal blood vessels, tumor vessels consist of endothelial cells, mural cells (pericytes and smooth muscle cells), and basement membrane (Baluk et al. 2003). The expression of α-SMA was restricted to vascular smooth muscle cells and co-localized with CD31 (Figure 2D). Interestingly, we noticed that blood vessels from AsT/miR-199a tumors had many more mural cells reflected by α-SMA immunoreactivities than AsT/miR-cont tumors, suggesting that miR-199a decreases arsenic-induced tumor angiogenesis but promotes blood vessel maturation (Figure 2E).
miR-199a directly targets both HIF-1α and COX-2. HIF-1 is one of the major pro-angiogenic factors through inducing transcriptional activation of vascular endothelial growth factor (VEGF) (Semenza 2000). Another potent angiogenic activator for tumor angiogenesis is COX-2, which is a rate-limiting enzyme in the conversion of arachadonic acid precursors in the cell membrane into PGE2 (Xue and Shah 2013). COX-2 and HIF-1α expression are frequently regulated by similar stimuli and control similar processes within the cells (Gately 2000; Liu et al. 1999). In the present study, we observed that basal levels of HIF-1α and COX-2 under normoxia were markedly up-regulated in AsT cells (Figure 3A). Rane et al. (2009) reported that miR-199a directly targets HIF-1α in cardiac myocytes. Indeed, overexpression of miR-199a in AsT suppressed HIF-1α expression (Figure 3B). Interestingly, we noticed that miR-199a was also capable of down-regulating COX-2 expression. To explore whether COX-2 can be directly targeted by miR-199a, we used the “target search” process to predict possible binding sites and free minimal energy of bindings and found that COX-2 is a putative target of miR-199a with two potential binding regions. COX-2 3´UTR luciferase reporters containing two putative miR-199a binding sites were constructed to validate the direct binding between COX-2 mRNA 3´UTR and miR-199a. Co-transfection of miR-199a precursor with wild-type reporter constructs containing binding sites (COX-2 3´UTR 311/320) greatly decreased the luciferase activities in BEAS-2B cells, whereas co-transfection with the corresponding reporter containing point mutant at putative miR-199a binding sites did not affect the luciferase activities (Figure 3C). The luciferase activity in reporters containing putative binding sites in COX-2 3´UTR from 2021 to 2029 was not affected by miR-199a, which suggests that this computation-predicted site is not functionally targeted by miR-199a (Figure 3D). Consistently, the expression levels of COX-2 in xenograft tumors were generally lower in AsT/miR-199a groups than those in AsT/miR-cont groups (Figure 3E). These findings demonstrate that COX-2 is a novel direct target of miR-199a.
HIF-1α directly regulates COX-2 at the transcriptional level. We previously found that HIF-1α can be strongly induced by acute arsenic treatment in prostate cancer cells under normoxia condition (Gao et al. 2004). In this study, we observed that both HIF-1α and COX-2 expression levels were dramatically up-regulated in AsT cells. We speculate whether there is an interaction between HIF-1α and COX-2 in this context. The COX-2 promoter contains several HREs, one of which we predicted to be functional (Jiang et al. 2009). In the present study, we first investigated whether HIF-1α is required for arsenic-induced COX-2 expression. COX-2 mRNA and protein levels in BEAS-2B cells were up-regulated under the hypoxia condition, whereas knockdown of HIF-1α by specific siRNA almost completely reversed the induction (Figures 4A-B). This indicates that hypoxia stimulates COX-2 expression via HIF-1α. We further measured the concentration of COX-2 product, PGE2, with the same treatments. Both BEAS-2B cells and AsT cells produced more PGE2 under hypoxia. Conversely, knockdown of HIF-1α decreased PGE2 concentration with hypoxic treatment (Figure 4C). To determine if there is a direct interaction between HIF-1α and COX-2 promoter, we performed the ChIP assay. BEAS-2B cells were cultured in hypoxic chamber for 24h and were subjected to ChIP assay. As shown in Figure 4D, antibody against HIF-1α was able to pull down COX-2 promoter suggesting the association between HIF-1α and COX-2 gene. The earlier findings in our group predicted that one of HRE (-576/-584) in the COX-2 promoter would be functional (Jiang et al. 2009). We validated the binding sites by constructing COX-2 promoter luciferase reporters with wild-type or mutant HRE. As shown in Figure 4E, hypoxia stimulated COX-2 transcriptional activity measured by luciferase activity in BEAS-2B cells transfected with wild-type reporter. Conversely, BEAS-2B cells transfected with mutant reporter weren’t affected by hypoxia. Furthermore, co-transfection of HIF-1α with the wild-type reporter similarly promoted COX-2 transcription while co-transfection with the mutant reporter did not affect the luciferase activities (Figure 4F). Collectively, these data support that HIF-1α directly regulates COX-2 at the transcriptional level.
miR-199a inhibits arsenic-induced angiogenesis via COX-2 expression. To determine the role of COX-2 in arsenic-induced angiogenesis, we knocked down COX-2 to evaluate the angiogenesis response using the CAM assay (Figure 5A). We observed a dramatic decrease of angiogenic potential in COX-2 knockdown cells (Figure 5B). To test whether the overexpression of COX-2 without miR-199a binding sites is able to reverse miR-199a–inhibited angiogensis in AsT cells, we established stable AsT cells overexpressing COX2 by transducing lentivirus carrying COX-2 cDNA without 3´UTR region. We observed that forced expression of COX-2 completely reversed the inhibitory effect of miR-199a in angiogenesis (Figure 5C). Taken together, these results suggest that miR-199a inhibits arsenic-induced angiogenesis by directly targeting COX-2 expression.
ROS induce COX-2 pathway by suppressing miR-199a in AsT cells. Induction of ROS in cells is closely related with heavy metal exposure including arsenic, chromium, and cadmium (Azad et al. 2010; Huang et al. 2004; Wang et al. 2012). We previously observed that AsT cells produced higher ROS (Carpenter et al. 2011). In addition, our earlier findings indicate that miR-199a is a ROS responsive miRNA in which ROS inhibit miR-199a expression through increasing the promoter methylation of miR-199a gene by DNA methyltransferase 1 (He et al. 2012b). In this study, we found that ROS treatment increased COX-2 expression, whereas the ROS scavenger catalase decreased COX-2 expression (Figure 6A). To investigate whether ROS are upstream signals for inhibiting miR-199a expression, we treated AsT cells stably overexpressing miR-199a and AsT control cells with H2O2. We found that H2O2–induced COX-2 expression in AsT/miR-cont cells, but no induction was observed in AsT/miR-199a cells (Figure 6B).
The strong links between the aberration of miRNAs profiles and carcinogenesis, cancer development, prognosis and chemoresistance have been confirmed by a plethora of bench and clinical studies (reviewed by Iorio and Croce 2012). In this study, we identified that exposure to arsenic induced the suppression of miR-199a expression, which led to increased angiogenesis responses and tumor growth.
The process of angiogenesis normally occurs in the embryo, placenta, and during menstrual cycle and wound-healing (Patella and Rainaldi 2012). However, under pathological situations such as cancer, the same angiogenic signaling pathways in tumors are induced in order to obtain the sufficient blood supply for tumor growth. A number of miRNAs have been reported to be involved in blood vessel development and angiogenesis by directly or indirectly regulating pro-angiogenic factors or anti-angiogenic factors (Hua et al. 2006; Poliseno et al. 2006; Urbich et al. 2008). Our previous study (He et al. 2013a) showed that miR-199a inhibits tumor angiogenesis by targeting ERBB2 and ERBB3 thus suppressing their downstream VEGF in ovarian cancer cells. In the context of arsenic-induced transformation, miR-199a showed strong anti-angiogenic properties not only by directly targeting HIF-1α but also another proangiogenic factor COX-2, which highlights the important role of miR-199a in angiogenesis. Tumor vessels are leaky, immature, or morphologically abnormal because of the absent or incomplete basement membrane and mural cells (pericytes and smooth muscle cells). Failure of tumor vessels to recruit a normal coat of mural cells may contribute to the abnormality of vessels (Abramsson et al. 2002). Berthod et al. (2012) showed that α-SMA expressing cells were present around capillaries and can thus act as a pericyte marker. Interestingly, we found that miR-199a can not only reduce the total number of microvessels in tumors but also promote vascular maturation as indicated by the higher α-SMA staining.
HIF-1α signaling plays a critical role in tumor metastasis, invasion, metabolism, and, especially, angiogenesis (Covello and Simon 2004; Lum et al. 2007). We found that the baseline of HIF-1α expression, which is oxygen independent, was dramatically up-regulated in arsenic-transformed cells. The underlying mechanism might be the activation of thymoma viral oncogene (AKT), mitogen-activated protein kinase (ERK), mechanistic target of rapamycin (serine/threonine kinase; mTOR), and ribosomal protein S6 kinase, polypeptide 1 (p70S6K1) genes, as suggested by our earlier results (Carpenter et al. 2011). A recent study reported that overexpression of miR-199a inhibited the hypoxia-induced cell proliferation in non-small cell lung cancer by suppressing HIF-1α (Ding et al. 2013). Oltipraz, a cancer chemopreventive agent, has anti-angiogenic property mediated by miR-199a induction and HIF-1α inhibition (Kang et al. 2012). Consistent with the report of Kang et al. (2012), our results show that miR-199a suppression by arsenic exposure releases its direct target inhibition of HIF-1α. More importantly, we also validated that COX-2 is a novel target of miR-199a and is functional in AsT cells. The COX-2 expression was almost undetectable in parental BEAS-2B cells, but it was pronouncedly expressed after chronic arsenic exposure. Our functional study revealed that COX-2 plays an important role in arsenic-induced angiogenesis, which can be impaired by miR-199a overexpression. Furthermore, consistent with other studies (Csiki et al. 2006; Kaidi et al. 2006), both protein-DNA binding assay and luciferase reporter assay confirmed that HIF-1α directly regulates COX-2 expression in parental BEAS-2B cells. This result along with data that PGE2 can stimulate VEGF expression through the activation of HIF-1α (Greenhough et al. 2009) suggests a positive-feedback between HIF-1α and COX-2 in arsenic-induced angiogenesis. The findings also indicate that miR-199a may have high therapeutic efficiency as a tumor suppressor by targeting both HIF-1α and COX-2. In addition, miR-199a-3p has also been reported to target COX-2 in human chondrocytes (Akhtar and Haqqi 2012). Because miR-199a-3p and miR-199a-5p (miR-199a) are derived from the same precursor, the expression levels of both miRNAs may be somewhat regulated by the same mechanism(s). Further investigation of the upstream molecules that may indirectly modulate COX-2 expression via both miRNAs in the future is of interest.
Overproduction of ROS is closely related to heavy metal–mediated carcinogenesis (Lee et al. 2012). Oxidative stress was reported as a mediator of arsenic-induced cell transformation and carcinogenesis (Carpenter et al. 2011; Wang et al. 2012). In addition, ROS can activate HIF-1α and COX-2 in various contexts (Bonello et al. 2007; Chen et al. 2012). However, the mechanism underlying how ROS regulate HIF-1α and COX-2 remains to be investigated. Here, we provide a link in which repression of miR-199a by arsenic-induced ROS activates HIF-1α and COX-2 expression.
We found similar miR-199a suppression and HIF-1α/COX-2 activation in Cr (VI)–transformed cells (see Supplemental Material, Figure S3). Further investigation is needed to determine whether the same pathway is generally activated in other metal-induced cell transformation.
The present study provides a new mechanism of arsenic-induced tumor angiogenesis and tumor growth. Arsenic-induced ROS inhibit miR-199a expression via DNMT1-mediated DNA methylation. The repression of miR-199a expression results in induction of HIF-1α and COX-2. In addition, the bidirectional regulations between HIF-1α and COX-2 forming a positive feedback further promote tumor angiogenesis and tumor growth (Figure 6C). Our findings may have clinical implication in targeted therapy for arsenic-induced lung cancer in the future.
Azad N, Iyer A, Vallyathan V, Wang L, Castranova V, Stehlik C, et al. 2010. Role of oxidative/nitrosative stress-mediated Bcl-2 regulation in apoptosis and malignant transformation. Ann NY Acad Sci 1203:1–6.
Beezhold K, Liu J, Kan H, Meighan T, Castranova V, Shi X, et al. 2011. miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis. Toxicol Sci 123:411–420.
Bonello S, Zähringer C. , BelAiba RS, Djordjevic T, Hess J, Michiels C, et al. 2007. Reactive oxygen species activate the HIF-1α promoter via a functional NFκB site. Arterioscler Thromb Vasc Biol 27:755–761.
Carpenter RL, Jiang Y, Jing Y, He J, Rojanasakul Y, Liu LZ, et al. 2011. Arsenite induces cell transformation by reactive oxygen species, AKT, ERK1/2, and p70S6K1. Biochem Biophys Res Commun 414:533–538.
Chen CC, Cheng YY, Chen SC, Tuan YF, Chen YJ, Chen CY, et al. 2012. Cyclooxygenase-2 expression is up-regulated by 2-aminobiphenyl in a ROS and MAPK-dependent signaling pathway in a bladder cancer cell line. Chem Res Toxicol 25:695–705.
Chen CL, Hsu LI, Chiou HY, Hsueh YM, Chen SY, Wu MM, et al. 2004. Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. JAMA 292:2984–2990.
Csiki I, Yanagisawa K, Haruki N, Nadaf S, Morrow JD, Johnson DH, et al. 2006. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1α in non-small cell lung cancer. Cancer Res 66:143–150.
Ding G, Huang G, Liu HD, Liang HX, Ni YF, Ding ZH, et al. 2013. MiR-199a suppresses the hypoxia-induced proliferation of non-small cell lung cancer cells through targeting HIF1α. Mol Cell Biochem 2013. 384(1–2):173–180.
Fero Lab, Fred Hutchinson Cancer Research Center. 2011. Tissue Processing and Sectioning. Available: http://labs.fhcrc.org/fero/Protocols/processing.html [accessed 28 January 2014].
Gao N, Shen L, Zhang Z, Leonard SS, He H, Zhang XG, et al. 2004. Arsenite induces HIF-1α and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol Cell Biochem 255:33–45.
Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. 2009. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30:377–386.
He J, Jing Y, Li W, Qian X, Xu Q, Li FS, et al. 2013a. Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis. PLoS One 8:e56647; doi: 10.1371/journal.pone.0056647.
He J, Xu Q, Wang M, Li C, Qian X, Shi Z, et al. 2012a. Oral administration of apigenin inhibits metastasis through AKT/P70S6K1/MMP-9 pathway in orthotopic ovarian tumor model. Int J Mol Sci 13:7271–7282.
Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, et al. 2006. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 1:e116; doi: 10.1371/journal.pone.0000116.
Hubaux R, Becker-Santos DD, Enfield KS, Rowbotham D, Lam S, Lam WL, et al. 2013. Molecular features in arsenic-induced lung tumors. Mol Cancer 12:20; doi: 10.1186/1476-4598-12-20.
Jiang BH, Zheng JZ, Aoki M, Vogt PK. 2000. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 97:1749–1753.
Jiang Y, Cukic B, Adjeroh DA, Skinner HD, Lin J, Shen QJ, et al. 2009. An algorithm for identifying novel targets of transcription factor families: application to hypoxia-inducible factor 1 targets. Cancer Inform 7:75–89.
Kaidi A, Qualtrough D, Williams AC, Paraskeva C. 2006. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 66:6683–6691.
Kang SG, Lee WH, Lee YH, Lee YS, Kim SG. 2012. Hypoxia-inducible factor-1α inhibition by a pyrrolopyrazine metabolite of oltipraz as a consequence of microRNAs 199a-5p and 20a induction. Carcinogenesis 33:661–669.
Kolligs FT, Hu G, Dang CV, Fearon ER. 1999. Neoplastic transformation of RK3E by mutant β-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol 19:5696–5706.
Liu XH, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, et al. 1999. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 17:687–694.
Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, et al. 2007. The transcription factor HIF-1α plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 21:1037–1049.
Rahman MM, Chowdhury UK, Mukherjee SC, Mondal BK, Paul K, Lodh D, et al. 2001. Chronic arsenic toxicity in Bangladesh and West Bengal, India—a review and commentary. J Toxicol Clin Toxicol 39:683–700.
Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J, et al. 2009. Downregulation of miR-199a derepresses hypoxia-inducible factor-1α and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 104:879–886.
U.S. Environmental Protection Agency. 2014. Drinking Water Contaminants. Available: http://water.epa.gov/drink/contaminants/index.cfm#two [accessed 30 January 2014].
Wang X, Mandal AK, Saito H, Pulliam JF, Lee EY, Ke ZJ, et al. 2012. Arsenic and chromium in drinking water promote tumorigenesis in a mouse colitis-associated colorectal cancer model and the potential mechanism is ROS-mediated Wnt/β-catenin signaling pathway. Toxicol Appl Pharmacol 262:11–21.
Wang Z, Zhao Y, Smith E, Goodall GJ, Drew PA, Brabletz T, et al. 2011. Reversal and prevention of arsenic-induced human bronchial epithelial cell malignant transformation by microRNA-200b. Toxicol Sci 121:110–122.
CEHN July 2015 Article of the Month
“In Utero and Childhood Polybrominated Diphenyl Ether Exposures and Body Mass at Age 7 Years: The CHAMACOS Study” (DOI:10.1289/ehp.1408417) has been selected by the Children’s Environmental Health Network (CEHN) as its July 2015 Article of the Month. These CEHN summaries discuss the potential policy implications of current children’s environmental health research.
2014 Impact Factor
EHP is pleased to announce its new impact factor of 7.98, up from 7.03 last year. EHP is now ranked 2nd of 87 journals in Toxicology, 3rd of 162 journals in Public, Environmental and Occupational Health, and 4th of 221 journals in Environmental Sciences. We thank our authors and readers for their contributions and support.
Sign Up to Receive E-mail Alerts
Recent Advance Publications
Multiple Trigger Points for Quantifying Heat-Health Impacts: New Evidence from a Hot Climate
Environmental Chemicals in Urine and Blood: Improving Methods for Creatinine and Lipid Adjustment
Satellite-Based Spatiotemporal Trends in PM2.5 Concentrations: China, 2004–2013
Desert Dust Outbreaks in Southern Europe: Contribution to Daily PM10 Concentrations and Short-Term Associations with Mortality and Hospital Admissions
Exposure to Bisphenol A and Phthalates during Pregnancy and Ultrasound Measures of Fetal Growth in the INMA-Sabadell Cohort